JP6377123B2 - 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 - Google Patents
癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 Download PDFInfo
- Publication number
- JP6377123B2 JP6377123B2 JP2016502187A JP2016502187A JP6377123B2 JP 6377123 B2 JP6377123 B2 JP 6377123B2 JP 2016502187 A JP2016502187 A JP 2016502187A JP 2016502187 A JP2016502187 A JP 2016502187A JP 6377123 B2 JP6377123 B2 JP 6377123B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- pharmaceutical composition
- chlorophenyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QPWPHXQCCIMHAL-PICXLURJSA-N CC(C)(C)S(CC(C1CC1)N(C(C(c1cc(Cl)ccc1)O[C@]1(C)Cc(nc2)ccc2C(O)=O)C(/C=C\C(\Cl)=C(/C)\F)=C)C1=O)(=O)=O Chemical compound CC(C)(C)S(CC(C1CC1)N(C(C(c1cc(Cl)ccc1)O[C@]1(C)Cc(nc2)ccc2C(O)=O)C(/C=C\C(\Cl)=C(/C)\F)=C)C1=O)(=O)=O QPWPHXQCCIMHAL-PICXLURJSA-N 0.000 description 1
- IRQSKJQDKUAART-UHFFFAOYSA-N COC(c1cnc(CBr)cc1)=O Chemical compound COC(c1cnc(CBr)cc1)=O IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 1
- WNPSSFSXORYRAN-WXOOSPASSA-N C[C@@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2F)ccc2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2F)ccc2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 WNPSSFSXORYRAN-WXOOSPASSA-N 0.000 description 1
- HKNCPEFDFMIXFA-PZEHHVJRSA-N C[C@@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 HKNCPEFDFMIXFA-PZEHHVJRSA-N 0.000 description 1
- WNPSSFSXORYRAN-WZCQUIKNSA-N C[C@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@](CC=C)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 WNPSSFSXORYRAN-WZCQUIKNSA-N 0.000 description 1
- HKNCPEFDFMIXFA-HEXBMGIASA-N C[C@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@](Cc(nc1)ccc1C(OC)=O)(C(N(C(CO)C1CC1)C1c(cc2)cc(F)c2Cl)=O)O[C@@H]1c1cc(Cl)ccc1 HKNCPEFDFMIXFA-HEXBMGIASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784230P | 2013-03-14 | 2013-03-14 | |
| US61/784,230 | 2013-03-14 | ||
| PCT/US2014/026584 WO2014151863A1 (en) | 2013-03-14 | 2014-03-13 | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513660A JP2016513660A (ja) | 2016-05-16 |
| JP2016513660A5 JP2016513660A5 (enExample) | 2017-03-30 |
| JP6377123B2 true JP6377123B2 (ja) | 2018-08-22 |
Family
ID=50442720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502187A Active JP6377123B2 (ja) | 2013-03-14 | 2014-03-13 | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9758495B2 (enExample) |
| EP (1) | EP2970237B1 (enExample) |
| JP (1) | JP6377123B2 (enExample) |
| AU (1) | AU2014236812B2 (enExample) |
| CA (1) | CA2906538C (enExample) |
| MX (1) | MX374513B (enExample) |
| WO (1) | WO2014151863A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| SMT202200241T1 (it) | 2013-11-11 | 2022-09-14 | Amgen Inc | Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN107428734A (zh) | 2015-01-20 | 2017-12-01 | 阿尔维纳斯股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| IL304982A (en) | 2016-11-01 | 2023-10-01 | Arvinas Operations Inc | PROTACS Targeted Tau-Protein and Related Methods of Use |
| LT3689868T (lt) | 2016-12-01 | 2023-12-27 | Arvinas Operations, Inc. | Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| JP7679173B2 (ja) | 2016-12-23 | 2025-05-19 | アルビナス・オペレーションズ・インコーポレイテッド | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| KR20230140606A (ko) | 2017-01-26 | 2023-10-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법 |
| WO2019020501A1 (en) | 2017-07-28 | 2019-01-31 | Basf Se | Preparation of substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| WO2019038042A1 (en) | 2017-08-21 | 2019-02-28 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| WO2019219464A1 (en) | 2018-05-15 | 2019-11-21 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| JP7656589B2 (ja) | 2019-08-26 | 2025-04-03 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法 |
| CN114761387A (zh) | 2019-12-05 | 2022-07-15 | 巴斯夫欧洲公司 | 取代的芳族羧酰胺的制备 |
| CN115315419A (zh) | 2020-04-29 | 2022-11-08 | 巴斯夫欧洲公司 | 通过钯催化的羰基化反应制备芳族羧酰胺 |
| CN115298163B (zh) | 2020-04-29 | 2024-11-19 | 巴斯夫欧洲公司 | 通过钯催化的羰基化反应制备芳族羧酰胺 |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| TW202214236A (zh) | 2020-09-14 | 2022-04-16 | 美商亞文納營運公司 | 用於靶向降解雌激素受體之化合物之結晶及非晶形形式 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH436295A (de) | 1961-11-13 | 1967-05-31 | Mcneilab Inc | Verfahren zur Herstellung neuer 3-Morpholinone |
| US3518236A (en) | 1967-07-20 | 1970-06-30 | Uniroyal Inc | Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JP2604472B2 (ja) | 1989-07-12 | 1997-04-30 | 株式会社クラレ | 重合性組成物 |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| DK0776324T3 (da) | 1994-08-19 | 2002-10-07 | Abbott Lab | Endothelin-antagonister |
| CA2634973A1 (en) | 1996-02-13 | 1997-08-21 | Abbott Laboratories | Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| AUPO527597A0 (en) * | 1997-02-24 | 1997-03-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compounds |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| TR200101234T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU1910299A (en) | 1997-12-18 | 1999-07-05 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US7214540B2 (en) | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
| US6630006B2 (en) | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
| US7052545B2 (en) | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
| US7195670B2 (en) | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| US7229500B2 (en) | 2000-11-20 | 2007-06-12 | Parallel Synthesis Technologies, Inc. | Methods and devices for high throughput crystallization |
| EP1358178A2 (en) | 2001-01-30 | 2003-11-05 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
| US6858600B2 (en) | 2001-05-08 | 2005-02-22 | Yale University | Proteomimetic compounds and methods |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| CN100486969C (zh) | 2001-12-18 | 2009-05-13 | 霍夫曼-拉罗奇有限公司 | 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用 |
| US6860940B2 (en) | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| ATE414693T1 (de) | 2004-05-18 | 2008-12-15 | Hoffmann La Roche | Neuartige cis-imidazoline |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| EP1809282B1 (en) | 2004-10-18 | 2013-01-09 | Amgen, Inc | Thiadiazole compounds and methods of use |
| MX2007011151A (es) | 2005-03-16 | 2007-10-17 | Hoffmann La Roche | Cis-2,4,5-triaril-imidazolinas y su uso como medicamentos anticancer. |
| KR20080007233A (ko) | 2005-04-04 | 2008-01-17 | 에자이 가부시키가이샤 | 두통용 디히드로피리딘 화합물 및 조성물 |
| WO2007063013A1 (en) | 2005-12-01 | 2007-06-07 | F. Hoffmann-La Roche Ag | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
| AU2007207743B2 (en) | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| BRPI0713119A2 (pt) | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
| JP2009543865A (ja) | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド | ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤 |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| PT2139882E (pt) | 2007-03-23 | 2014-01-30 | Amgen Inc | Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k) |
| WO2008118454A2 (en) | 2007-03-23 | 2008-10-02 | Amgen Inc. | Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer |
| HUE028954T2 (en) | 2007-03-23 | 2017-01-30 | Amgen Inc | Heterocyclic compounds and their use |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| EP2176238B1 (en) | 2007-07-09 | 2012-04-18 | AstraZeneca AB | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| CA2693473A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| CA2694136C (en) | 2007-08-02 | 2013-09-17 | Amgen Inc. | Pi3 kinase modulators and methods of use |
| AU2008309759A1 (en) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral CIS-imidazolines |
| WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| JP2011507799A (ja) | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癲癇のためのａｍｐａ受容体アンタゴニストおよびゾニサミド |
| EP2268616A1 (en) | 2008-03-21 | 2011-01-05 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| WO2009126584A1 (en) | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| BRPI0919325A2 (pt) | 2008-09-18 | 2021-03-30 | F.Hoffmann-La Roche Ag | Pirrolidina-2-carboxamidas substituídas |
| EP2387570A1 (en) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| MX2011008674A (es) | 2009-02-18 | 2011-11-04 | Amgen Inc | Compuestos de indol/bencimidazol como inhibidores de quinasa mtor. |
| JP2012521354A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| WO2010132598A1 (en) | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| JP2012531438A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびその使用 |
| JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用 |
| MX2011013901A (es) | 2009-06-25 | 2012-05-08 | Amgen Inc | Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. |
| EP2445900B1 (en) | 2009-06-25 | 2016-03-02 | Amgen, Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| US20120149661A1 (en) | 2009-08-26 | 2012-06-14 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| JP6417338B2 (ja) | 2013-02-19 | 2018-11-07 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 |
| JP6266659B2 (ja) | 2013-02-28 | 2018-01-24 | アムジエン・インコーポレーテツド | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| SMT202200241T1 (it) | 2013-11-11 | 2022-09-14 | Amgen Inc | Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri |
-
2014
- 2014-03-13 WO PCT/US2014/026584 patent/WO2014151863A1/en not_active Ceased
- 2014-03-13 AU AU2014236812A patent/AU2014236812B2/en active Active
- 2014-03-13 US US14/774,645 patent/US9758495B2/en active Active
- 2014-03-13 CA CA2906538A patent/CA2906538C/en active Active
- 2014-03-13 EP EP14716176.4A patent/EP2970237B1/en active Active
- 2014-03-13 MX MX2015012427A patent/MX374513B/es active IP Right Grant
- 2014-03-13 JP JP2016502187A patent/JP6377123B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9758495B2 (en) | 2017-09-12 |
| WO2014151863A1 (en) | 2014-09-25 |
| CA2906538C (en) | 2021-02-02 |
| AU2014236812A1 (en) | 2015-09-17 |
| EP2970237B1 (en) | 2017-09-27 |
| MX2015012427A (es) | 2016-01-12 |
| US20160039774A1 (en) | 2016-02-11 |
| CA2906538A1 (en) | 2014-09-25 |
| JP2016513660A (ja) | 2016-05-16 |
| AU2014236812B2 (en) | 2018-03-01 |
| EP2970237A1 (en) | 2016-01-20 |
| MX374513B (es) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6377123B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 | |
| JP6093770B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 | |
| JP6077695B2 (ja) | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 | |
| JP6266659B2 (ja) | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 | |
| JP6417338B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 | |
| US11407721B2 (en) | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | |
| WO2013123444A1 (en) | Sulfonyl compounds that interact with glucokinase regulatory protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170222 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180611 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180710 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180724 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6377123 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |